Article
Proximity proteome mapping reveals PD-L1-dependent pathways disrupted by anti-PD-L1 antibody specifically in EGFR-mutant lung cancer cells.
Cell communication and signaling : CCS - 13 Mar 2023
Letian Anudari, Lemma Eyoel Yemanaberhan, Cavaliere Paola, Dephoure Noah, Altorki Nasser K, McGraw Timothy E
Abstract excerpt
BACKGROUND: PD-L1, a transmembrane ligand for immune checkpoint receptor PD1, has been successfully targeted to activate an anti-tumor immune response in a variety of solid tumors, including non-small cell lung cancer (NSCLC). Despite the success of targeting PD-L1, only about 20% of patients achieve a durable response. The reasons for the heterogeneity in response are not understood, although some molecular...
Topics
Join the communities discussing this publication.